Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

pembrolizumab 30Cisplatin 18Nivolumab 15Cyclophosphamide 14Carboplatin 14Paclitaxel 13Radiation 12Doxorubicin 11Radiotherapy 10Radiotherapy, Intensity-Modulated 9Magnetic Resonance Spectroscopy 9Cytarabine 9Vincristine 8Radiosurgery 8Docetaxel 8Bevacizumab 8Pemetrexed 7Metformin 7Leucovorin 7Injections 7Fluorouracil 7Etoposide 7venetoclax 6Specimen Handling 6Prednisone 6Letrozole 6Irinotecan 6Ipilimumab 6Gemcitabine 6Dexamethasone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pegloticase × 30 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡